Sanofi-logo

For US Healthcare Professional use only.
The safety and efficacy of these investigational agents have not been established.
Atopic Dermatitis

An Open-label, Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Atopic Dermatitis (ATLANTIS)

An Open-label, Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Atopic Dermatitis (ATLANTIS)
An Open-label, Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Atopic Dermatitis (ATLANTIS) Scan and Download Back

Privacy & Data Protection        Cookies Policy
Does not include study cards for clinical programs of dupilumab.

MAT-US-2401225 v1.0 - P Exp. Date: 02/12/2026
© 2024 Sanofi. All rights reserved.